{"analyses":[{"groupDescription":"Comparison to a fixed efficacy target of 10%. H0: p ≤ 0.10 versus H1: p \\> 0.10","groupIds":["OG000"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0306","pValueComment":"one-sided p-value","statisticalMethod":"exact binomial distribution"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"11.1","upperLimit":"38.3","value":"22.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"31"}],"units":"Participants"}],"description":"CRR was defined as the percentage of participants with complete remission according to the revised response criteria for malignant lymphoma per Cheson et al. 2007. Complete remission was demonstrated by disappearance of all evidence of disease in the bone marrow, spleen, liver, and lymph nodes. Cohort 3 was evaluated statistically by comparing the complete remission for pembrolizumab to a fixed efficacy target of 10% using a binomial exact test. The percentage of participants with complete remission as assessed by the investigator is presented.","dispersionType":"90% Confidence Interval","groups":[{"description":"Participants received pembrolizumab 10 mg/kg by IV infusion on Day 1 of each 14-day cycle.","id":"OG000","title":"Cohort 3: Relapsed/Refractory (R/R) Hodgkin Lymphoma (HL)"}],"paramType":"NUMBER","populationDescription":"All participants in Cohort 3 with a baseline efficacy evaluation and at least 1 post-baseline efficacy evaluation.","reportingStatus":"POSTED","timeFrame":"Up to approximately 78.5 months","title":"Complete Remission Rate (CRR) in Cohort 3: Relapsed/Refractory (R/R) Hodgkin Lymphoma (HL)","type":"PRIMARY","unitOfMeasure":"Percentage of participants"}